Sanofi (SNY) Tops Q4 EPS by 53c; offers outlook

Sanofi (NASDAQ: SNY) reported Q4 EPS of EUR1.31, EUR0.53 better than the analyst estimate of EUR0.78. Revenue for the quarter came in at EUR10.56 billion versus the consensus estimate of EUR12.38 billion.

OUTLOOK

In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5. Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)

For earnings history and earnings-related data on Sanofi (SNY) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• NeuroSense posts narrower H1 loss, targets Canada drug filing by December
• Pentagon-Backed Oil Company Is Set to Vie for Chevron's Crown in Venezuela - WSJ